Date: 2016-05-26
Type of information: Commercialisation agreement
Compound:
Company: Oasmia Pharmaceutical (Sweden)
Therapeutic area: Cancer - Oncology - Veterinary medicine
Type agreement: commercialisation
Action mechanism:
Disease:
Details: * On May 26, 2016, Oasmia Pharmaceutical, a developer of a new generation of drugs within human and veterinary oncology, announced its intent to identify international marketing, distribution, and development partners to facilitate entry into a number of key markets following anticipated but pending approval from regulatory bodies in Europe, the United States, and other regions throughout the world.
Oasmia has already initiated this process by hosting introductory and in-depth conversations with multiple potential partners. The company views this step as a crucial objective following its recent submissions (Paclical®/Apealea®), and its anticipated submission to the FDA in the end of 2016/2017. Oasmia believes it has bolstered the process with both entities following the recently released Overall Survival (OS) Phase III data results that it plans to add to and include in both submissions. Further, the Company has disclosed that it has reviewed term sheets for the licensing of its XR17 excipient technology, an innovative drug delivery program that the Company believes possesses significant potential across many pharmaceutical indications beyond the cytostatic drug market.
Oasmia has already secured distribution partners in Russia, Commonwealth of Independent States (CIS), Israel, and Turkey. The market for Oasmia’s first Human Health product Paclical/Apealea amounts to about $2 billion with very few players in this segment.
Financial terms:
Latest news:
